Universitätsmedizin Rostock, Abt. f. Hämatologie und Onkologie, Klinik und Poliklinik für Innere Medizin
Welcome,         Profile    Billing    Logout  
 4 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Junghanß, Christian
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
IMPACT-AML, NCT06713837: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

Not yet recruiting
3
339
Europe, RoW
High intensity therapies, Low intensity therapies
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European Leukemia Net, Fundacion Para La Investigacion Hospital La Fe, Ostdeutsche Studiengruppe Haematologie Und Onkologie e.V., Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, TIMELEX
Acute Myeloid Leukemia, Relapse/Recurrence
01/28
01/28
GRAPPA, NCT05153226: GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG

Active, not recruiting
3
640
Europe
Cyclophosphamide, all brands, ATG, ATG Grafalon
DKMS gemeinnützige GmbH
Graft Vs Host Disease, Peripheral Blood Stem Cell Transplantation, AML, MDS, MDS/MPN, CMML
06/25
12/26
AMBeR eBlood, NCT06809101: Home Monitoring of Complete Blood Count Performed by Patients - a Pilot Study on the Implementation Process in South Baltic Countries.

Not yet recruiting
N/A
265
Europe
Pomeranian Medical University Szczecin, University Clinical Centre, Gdansk, University Medicine Greifswald, University Medical Center Rostock, Zealand University Hospital
Cancer, Cancer-related Problem/Condition, Chemotherapy, Chemotherapy-induced Neutropenia, Chemotherapy Induced Anaemia, Chemotherapy Induced Thrombocytopenia
07/26
07/26
Große-Thie, Christina
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
Kragl, Brigitte
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
Henze, Larissa
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
NCT05008809: Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

Recruiting
3
507
Europe
mFOLFOX6, Folinic acid, Oxaliplatin, 5-fluorouracil (FU), mFOLFOXIRI, Folinic acid, Oxaliplatin, 5-FU, Irinotecan, FOLFIRI, Folinic acid, 5-FU, CAPOX, Capecitaine, Oxaliplatin
Dominik Paul Modest, German Research Foundation, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Colorectal Cancer
11/27
11/30

Download Options